President-elect Donald Trump's fiery stance on drug prices is putting pressure on pharmaceutical companies that may be designed to bring their support for his planned overhaul of the nation's health-care system.
Hours after Trump upended pharmaceutical stocks Wednesday with a pledge to force drugmakers to bid for government business, the U.S. Senate narrowly rejected a proposal to allow importation of cheaper prescription drugs from Canada. While votes on most amendments to the budget resolution went along party lines Wednesday night and Thursday morning, 12 Republicans supported the drug-import measure, with 13 Democrats opposed.
Bipartisan crossover in the 52-46 vote shows the drug pricing issue might have the power to unite enough members of both parties on legislation. Trump's remarks may have had the effect of bringing pharma companies to the table in repealing and replacing the Affordable Care Act, or Obamacare, which the president-elect has made a priority.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
